Last Year i send Newberry an email about this issue and well this was his answer,
I apologize for taking so long to reply. We have now had a couple of pieces of news this week that have consumed much of my time.
The military had shifting priorities and did not finish pursuing the program plan. The mechanism of action in Ebola and Marburg is thought to be similar to what we expect to see in the DIC study that is planned to start around the end of the year. It is possible that this research effort may take on a higher priority as we establish data in the DIC studies.
Best regards,
Tom
Thomas E. Newberry
Vice President, Corporate Communications
Phone: 508-370-5374
Fax: 508-370-3797
-----Original Message-----
From: L.H.Mulderij [mailto:l.h.mulderij@home.nl]
Sent: Monday, October 02, 2006 4:47 PM
To: Newberry, Thomas
Subject: CRADA
Dear Sir,
Can you tell me maby a bit more about two-year CRADA with the USAMRIID to evaluate the potential therapeutic application of ATryn to hemorrhagic diseases resulting from infections of the Ebola and Marburg viruses.
I ask this because the 2 year contract almost comes to an end and i can't remember that there was any news about this item recently, maby i mist something.
Sincerely,
L.H.Mulderij
Netherlands.
